Three new Toronto anti-cancer research companies were launched last month with investments from the Ontario Institute for Cancer Research (OICR). Frank Stonebanks, the organization's VP Commercialization said in an announcement that the new companies are among the "most promising new approaches" to the age-old fight against cancer.
TORCell Therapeutics, created by the University Health Network (UHN) and OICR, will focus on its first human clinical trials for a new treatment for acute myeloid leukemia.
DLVR Therapeutics, also a partnership between OICR and the UHN will take a potentially safer and more effective chemotherapy treatment developed by UHN doctor Gang Zheng and further develop the therapy.
Harmonic Medical, founded out of Sunnybrook Hospital, will perfect a prototype ultrasound therapy to destroy cancer cells and bring it to clinical trials.
"These three companies represent the best in Ontario innovation," provincial Innovation Minister Glen Murray said in a statement. Murray also said the investment in these companies will create "high-quality jobs" for researchers.
Writer: Edward Keenan
Source: Rhea Cohen, Director of Communications, OICR